1. Metabolic Enzyme/Protease
    Autophagy
  2. Phosphodiesterase (PDE)
    Autophagy
  3. Cilostazol

Cilostazol (Synonyms: OPC 13013)

Cat. No.: HY-17464 Purity: 99.91%
Handling Instructions

Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.

For research use only. We do not sell to patients.

Cilostazol Chemical Structure

Cilostazol Chemical Structure

CAS No. : 73963-72-1

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
50 mg USD 60 In-stock
Estimated Time of Arrival: December 31
100 mg USD 108 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 5 publication(s) in Google Scholar

Top Publications Citing Use of Products

Publications Citing Use of MCE Cilostazol

    Cilostazol purchased from MCE. Usage Cited in: Cardiovasc Eng Technol. 2019 Oct 17.

    Cilostazol increases cell proliferation in H/I cell models. The protein expression levels of p-AKT and p-eNOS and proliferation in HUVEC H/I cell model.

    Cilostazol purchased from MCE. Usage Cited in: Cardiovasc Eng Technol. 2019 Oct 17.

    Cilostazol increases cell proliferation in H/I cell models. The protein expression levels of p-AKT and p-eNOS and proliferation in VSMCH/I cell model. The protein expression is detected by western blotting, and cell proliferation was analyzed by DAPI/Brdu staining.

    Cilostazol purchased from MCE. Usage Cited in: Cardiovasc Eng Technol. 2019 Oct 17.

    Cilostazol increases cell proliferation in H/I cell models. The protein expression levels of p-AKT and p-eNOS and proliferation in VSMCH/I cell model.

    Cilostazol purchased from MCE. Usage Cited in: Cardiovasc Eng Technol. 2019 Oct 17.

    Cilostazol increases cell proliferation in H/I cell models. The protein expression levels of p-AKT and p-eNOS and proliferation in VSMCH/I cell model. The protein expression is detected by western blotting, and cell proliferation was analyzed by DAPI/Brdu staining.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

    IC50 & Target

    IC50: 0.2 μM ( PDE 3A)[1]

    In Vitro

    Cilostazol selectively inhibits cGMP-inhibited phosphodiesterase (PDE 3) and is a potent inhibitor of platelet aggregation induced by various agonists[2].
    Cilostazol inhibits stress-induced human platelet aggregation (SIPA) dose-dependently, with an IC50 of 15 μM for SIPA, and with a similar IC50 of 12.5 μM for ADP-induced platelet aggregation[2].
    Cilostazol directly and effectively inhibits the activation of HSC but not of Kupffer cells[3].

    In Vivo

    Cilostazol (100 mg; p.o.) produces a significant inhibition of SIPA in healthy volunteers[2].
    Cilostazol (clinically used doses; p.o.; for 2 weeks) could alleviate CCl4 -induced hepatic fibrogenesis in vivo, presumably due to its direct effect to suppress HSC activation[3].

    Animal Model: Male C57BL/6J mice[3]
    Dosage: 0.1% w/w, 0.3% w/w
    Administration: Oral administration; fed a normal diet for 2 weeks
    Result: Exhibited a lesser fibrotic area than control groups.
    Clinical Trial
    Molecular Weight

    369.46

    Formula

    C₂₀H₂₇N₅O₂

    CAS No.

    73963-72-1

    SMILES

    O=C1NC2=C(C=C(OCCCCC3=NN=NN3C4CCCCC4)C=C2)CC1

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 50 mg/mL (135.33 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7067 mL 13.5333 mL 27.0665 mL
    5 mM 0.5413 mL 2.7067 mL 5.4133 mL
    10 mM 0.2707 mL 1.3533 mL 2.7067 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

    *All of the co-solvents are provided by MCE.
    References

    Purity: 99.91%

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Keywords:

    CilostazolOPC 13013OPC13013OPC-13013Phosphodiesterase (PDE)AutophagyInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product name:
    Cilostazol
    Cat. No.:
    HY-17464
    Quantity:
    MCE Japan Authorized Agent: